Drug Database
Back to search

Netherlands· NL-042ed9c4d570

Rayvow 50 mg filmomhulde tabletten

A lasmiditan product containing lasmiditanhemisuccinaat, registered in Netherlands by Eli Lilly Nederland B.V.. The same ATC class is registered in 9 of our 19 countries.

ATC N02CC08

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedRayvow 50 mg filmomhulde tablettenATCN02CC08REGISTER NO.NL-042ed9c4d570PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lasmiditanhemisuccinaatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lasmiditan is registered in 9 of 19 countries.

Countries holding a registration under ATC N02CC08 (lasmiditan), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose
Search lasmiditan products by name

Lasmiditan · ATC N02CC08

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
LASMIDITANHEMISUCCINAAT
Manufacturer
Eli Lilly Nederland B.V.
Country
Netherlands (NL)
ATC code
N02CC08
ATC class
Lasmiditan
Defined daily dose
0.1 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/21/1587

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

191 interactions on record for lasmiditan.

Graded by severity as the source publishes them — 19 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lasmiditan against other medicinesHow interaction checks work

Lasmiditan · interactions on record

191 records

  • 19 severe
  • 172 moderate

Most severe, free to view

  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • DolasetronA04AA04severe
  • PalonosetronA04AA05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lasmiditan in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lasmiditan products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Rayvow
  • Liechtenstein · Rayvow
  • Norway · Rayvow

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7ba6535e-45b6-405f-a271-d8174c7c0729
GET /v1/drugs/7ba6535e-45b6-405f-a271-d8174c7c0729?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/rayvow-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Lasmiditan",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp127596",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "IJZEROXIDE ZWART (E 172)",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMLAURILSULFAAT",
    "POLYVINYLALCOHOL (E 1203)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)",
    "ZETMEEL, GEPREGELATINEERD"
  ],
  "substances": [
    "LASMIDITANHEMISUCCINAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2022/08/17",
  "procedure_number": "EMEA/H/C/005332",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/21/1587",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about lasmiditan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console